ArticlePloS one2012
Ivermectin inhibits growth of Chlamydia trachomatis in epithelial cells.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 31 citations in OpenAlex.
- Evaluating the Impact of Prophylactic Administration of Ivermectin on the Fecal Microbiome of Healthy C57BL/6J Mice (Mus musculus).Journal of the American Association for Laboratory Animal Science : JAALAS · 2026Article
- Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer.Cell death & disease · 2022Article
- Could the COVID-19-Driven Increased Use of Ivermectin Lead to Incidents of Imbalanced Gut Microbiota and Dysbiosis?Probiotics and antimicrobial proteins · 2022Review
- Ivermectin (IVM) Possible Side Activities and Implications in Antimicrobial Resistance and Animal Welfare: The Authors' Perspective.Veterinary sciences · 2022Article
- Ivermectin Impairs the Development of Sexual and Asexual Stages of Plasmodium falciparumAntimicrobial agents and chemotherapy · 2019Article
- Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles.Malaria journal · 2017Article
- Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations.The Journal of antibiotics · 2017Review
- Bioelectric regulation of innate immune system function in regenerating and intactNPJ Regenerative medicine · 2017Article
- Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?Nature reviews. Drug discovery · 2015Review
- Macrocyclic lactones differ in interaction with recombinant P-glycoprotein 9 of the parasitic nematode Cylicocylus elongatus and ketoconazole in a yeast growth assay.PLoS pathogens · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Ivermectin is currently approved for treatment of both clinical and veterinary infections by nematodes, including Onchocerca cervicalis in horses and Onchocerca volvulus in humans. However, ivermectin has never been shown to be effective against bacterial pathogens. Here we show that ivermectin also inhibits infection of epithelial cells by the bacterial pathogen, Chlamydia trachomatis, at doses that could be envisioned clinically for sexually-transmitted or ocular infections by Chlamydia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.